Redeye comments on Fluoguide’s Q1 2026 report. The quarter was marked by two consecutive FDA decisions that together define the near-term roadmap: authorisation to proceed with the first U.S. registration-directed Phase 2 trial in high-grade glioma (CT-006) and Fast Track Designation for FG001 in the same indication. The remainder of the year is set to be an eventful period for the company, with upcoming study data, the start of a study, and a possible partnership agreement. We reiterate our fair value range of SEK33-135, with a base case of SEK74.
LÄS MER
